Posted by Michael Wonder on 16 Feb 2023
Stimufend (pegfilgrastim-fpgk) now available in the United States
16 February 2023 - Fresenius Kabi introduces its first biosimilar in the US.
Fresenius Kabi announced today the immediate availability in the US of Stimufend (pegfilgrastim-fpgk), the company’s biosimilar to Neulasta (pegfilgrastim), for use in patients at risk for febrile neutropenia, a common side effect of many anti-cancer medications.
